TYK-ed Off由酒渣鼻-一个澳大利亚病例系列的酒渣鼻与Deucravacitinib。

IF 2.8 4区医学 Q1 DERMATOLOGY

Clinical and Experimental Dermatology Pub Date : 2025-09-17 DOI:10.1093/ced/llaf418

Zachary Warren, Chloe West, Christina Sander, Francis Lai

{"title":"TYK-ed Off由酒渣鼻-一个澳大利亚病例系列的酒渣鼻与Deucravacitinib。","authors":"Zachary Warren, Chloe West, Christina Sander, Francis Lai","doi":"10.1093/ced/llaf418","DOIUrl":null,"url":null,"abstract":"Deucravacitinib is a novel, oral selective Tyrosine kinase 2 (TYK2) inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. However, this report presents seven cases of prototypical papulopustular rosacea (PPR) following the commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy due to the severity and impact of their PPR. Rosacea as an adverse effect of deucravacitinib can be severe, impact on tolerability and influence future treatment options.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TYK-ed Off By Rosacea - An Australian Case Series of Rosacea Associated with Deucravacitinib.\",\"authors\":\"Zachary Warren, Chloe West, Christina Sander, Francis Lai\",\"doi\":\"10.1093/ced/llaf418\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Deucravacitinib is a novel, oral selective Tyrosine kinase 2 (TYK2) inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. However, this report presents seven cases of prototypical papulopustular rosacea (PPR) following the commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy due to the severity and impact of their PPR. Rosacea as an adverse effect of deucravacitinib can be severe, impact on tolerability and influence future treatment options.\",\"PeriodicalId\":10324,\"journal\":{\"name\":\"Clinical and Experimental Dermatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ced/llaf418\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ced/llaf418","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Deucravacitinib是一种新型的口服选择性酪氨酸激酶2 （TYK2）抑制剂，用于治疗斑块型银屑病。最常见的皮肤不良反应是痤疮和毛囊炎。然而，本报告提出了7例典型丘疹性酒渣鼻（PPR）开始后，deucravacitinib。虽然我们的大多数患者在deucravacitinib上表现出银屑病的改善，但由于其PPR的严重程度和影响，所有7名患者都停止了治疗。酒渣鼻作为德鲁瓦西替尼的不良反应可严重，影响耐受性并影响未来的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

TYK-ed Off By Rosacea - An Australian Case Series of Rosacea Associated with Deucravacitinib.

Deucravacitinib is a novel, oral selective Tyrosine kinase 2 (TYK2) inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. However, this report presents seven cases of prototypical papulopustular rosacea (PPR) following the commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy due to the severity and impact of their PPR. Rosacea as an adverse effect of deucravacitinib can be severe, impact on tolerability and influence future treatment options.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Experimental Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

2.40%

发文量

389

审稿时长

3-8 weeks

期刊介绍： Clinical and Experimental Dermatology (CED) is a unique provider of relevant and educational material for practising clinicians and dermatological researchers. We support continuing professional development (CPD) of dermatology specialists to advance the understanding, management and treatment of skin disease in order to improve patient outcomes.